title: Anticancer Drug Discovery and Development - SRI's Seventh Annual Summit.
authors.affiliation: Defined Healthcare Research Inc, Millburn, NJ 07041, USA. mrice@definedhealth.com
authors.forename: Michael C
authors.initials: MC
authors.lastname: Rice
authors.forename: Jeffrey
authors.initials: J
authors.lastname: Bockman
mesh_terms: D020533:Angiogenesis Inhibitors / Q000138:chemical synthesis* / Q000627:therapeutic use; D001549:Benzamides / Q000494:pharmacology / Q000627:therapeutic use; D002626:Chemistry, Pharmaceutical / Q000379:methods* / Q000639:trends; D002986:Clinical Trials as Topic / Q000379:methods; D003299:Cooperative Behavior; D004159:Diphenylamine / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use; D004345:Drug Industry / Q000379:methods; D015507:Drugs, Investigational / Q000627:therapeutic use; D006801:Humans; D000077269:Lenalidomide; D040541:Marketing / Q000379:methods; D010793:Phthalazines / Q000494:pharmacology / Q000627:therapeutic use; D010879:Piperazines / Q000494:pharmacology / Q000627:therapeutic use; D017346:Protein Serine-Threonine Kinases / Q000037:antagonists & inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D011720:Pyrazoles / Q000494:pharmacology / Q000627:therapeutic use; D011725:Pyridines / Q000494:pharmacology / Q000627:therapeutic use; D011804:Quinolines / Q000138:chemical synthesis / Q000494:pharmacology / Q000627:therapeutic use; D020794:Receptor Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors / Q000138:chemical synthesis / Q000627:therapeutic use; D000077294:Receptor, Transforming Growth Factor-beta Type II; D018125:Receptors, Transforming Growth Factor beta / Q000037:antagonists & inhibitors / Q000627:therapeutic use; D019089:Stem Cell Factor / Q000037:antagonists & inhibitors / Q000138:chemical synthesis / Q000627:therapeutic use; D013792:Thalidomide / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use; D013876:Thiophenes / Q000138:chemical synthesis / Q000627:therapeutic use; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D003521:Cyclopropanes; D011743:Pyrimidines
chemical_list: D020533:Angiogenesis Inhibitors; D001549:Benzamides; D004159:Diphenylamine; D015507:Drugs, Investigational; D000077269:Lenalidomide; D010793:Phthalazines; D010879:Piperazines; D017346:Protein Serine-Threonine Kinases; D011720:Pyrazoles; D011725:Pyridines; D011804:Quinolines; D020794:Receptor Protein-Tyrosine Kinases; D000077294:Receptor, Transforming Growth Factor-beta Type II; D018125:Receptors, Transforming Growth Factor beta; D019089:Stem Cell Factor; D013792:Thalidomide; D013876:Thiophenes; D042461:Vascular Endothelial Growth Factor A; C120227:2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide; C506615:HTS 466284; C505207:OSI 930; C484810:tozasertib; D003521:Cyclopropanes; D011743:Pyrimidines; C404768:vatalanib; C506614:mirdametinib